At present, only three predictive biomarkers–the assessment of microsatellite instability (MSI), tumor PD-L1 expression by immunohistochemistry, and the measurement of tumor mutation burden (TMB)8–10–have received approval from the U.S. Food and Drug Administration (FDA) for use as companion diagnostics for immunotherapy. Here, CD274 is linked to neoplasm.